GeneReach Biotechnology (4171) — Cash Flow Quality Index
GeneReach Biotechnology (4171) has a Cash Flow Quality Index of 4.33x as of December 2025. Operating cash flow of NT$12.05 Million exceeds net income of NT$2.79 Million, indicating high earnings quality where cash backs reported profits. Explore GeneReach Biotechnology cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
GeneReach Biotechnology Cash Flow Quality Index (2018–2022)
Historical Cash Flow Quality Index for GeneReach Biotechnology across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see cash flow conversion of GeneReach Biotechnology.
Annual Cash Flow Quality Index for GeneReach Biotechnology (2018–2022)
Year-by-year earnings quality comparison for GeneReach Biotechnology.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2022 | 1.62x | NT$357.63 Million | NT$221.34 Million | ▲ +117.3% |
| 2021 | 0.74x | NT$348.99 Million | NT$469.37 Million | ▲ +48.4% |
| 2020 | 0.50x | NT$169.82 Million | NT$338.94 Million | ▲ +445.5% |
| 2019 | -0.15x | NT$-11.19 Million | NT$77.18 Million | ▼ -172.1% |
| 2018 | 0.20x | NT$5.74 Million | NT$28.57 Million | — |